Students of Harvard University gather for their graduation ceremonies on Commencement Day

Harvard University Increased Its Bitcoin IBIT Stake By 257% In Q3: 'As Good A Validation As An ETF Can Get'

Harvard University significantly increased its stake in the iShares Bitcoin Trust ETF (NASDAQ:IBIT), according to the latest 13F filing released on Friday.

Harvard’s IBIT A ‘Good Validation’ For ETFs

Harvard Management Company, a wholly-owned subsidiary of Harvard University that manages its endowment, pension assets, and other financial assets, reported holding 6,813,612 shares of IBIT as of Sept. 30, a 257% jump from the previous quarter.

IBIT holdings made up 21% of Harvard’s investment portfolio, making it the fifth-biggest investment after Microsoft Corp. (NASDAQ:MSFT) and Amazon.com Inc. (NASDAQ:AMZN).

The stake was worth $442.88 million based on IBIT’s price of $65 on Sept. 30.

Bloomberg analyst Eric Balchunas noted that it’s “rare” for an endowment, especially from universities like Harvard and Yale, to invest in exchange-traded funds.

“It’s as good a validation as an ETF can get,” Balchunas stated.

See Also: Peter Schiff: Bitcoin Depends On ‘Growing Supply Of Fools’—And Technical Analysis Says He’s Not Wrong – Benzinga

IBIT Among Premier ETFs?

The iShares Bitcoin Trust, which debuted in January 2024, has emerged as a significant player in the ETF industry.

The fund has attracted nearly $27 billion this year, placing it among the top six ETFs by inflows, according to TradingView. It had $75 billion in assets under management as of this writing

Price Action: Shares of IBIT closed 3.80% lower at $53.48 during Friday’s regular trading session, according to data from Benzinga Pro.

Benzinga’s proprietary Edge Rankings show Momentum as the strongest category for IBIT at 44.33/100. To see how the stock ranks for Value, Growth and other indicators, click here.

Loading...
Loading...

Read Next: 

Photo Courtesy: f11photo on Shutterstock.com

Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

Comments
Loading...